204 related articles for article (PubMed ID: 25275045)
1. Gemtuzumab ozogamicin and olaparib exert synergistic cytotoxicity in CD33-positive HL-60 myeloid leukemia cells.
Yamauchi T; Uzui K; Nishi R; Shigemi H; Ueda T
Anticancer Res; 2014 Oct; 34(10):5487-94. PubMed ID: 25275045
[TBL] [Abstract][Full Text] [Related]
2. Induction of DNA strand breaks is critical to predict the cytotoxicity of gemtuzumab ozogamicin against leukemic cells.
Yamauchi T; Matsuda Y; Tasaki T; Negoro E; Ikegaya S; Takagi K; Yoshida A; Urasaki Y; Ueda T
Cancer Sci; 2012 Sep; 103(9):1722-9. PubMed ID: 22632031
[TBL] [Abstract][Full Text] [Related]
3. Granulocyte colony-stimulating factor enhances the in vitro cytotoxicity of gemtuzumab ozogamicin against acute myeloid leukemia cell lines and primary blast cells.
Rutella S; Bonanno G; Procoli A; Mariotti A; Lucia MB; Contemi AM; Cauda R; Fianchi L; Scambia G; Pagano L; Leone G
Exp Hematol; 2006 Jan; 34(1):54-65. PubMed ID: 16413391
[TBL] [Abstract][Full Text] [Related]
4. The cytotoxic effects of gemtuzumab ozogamicin (mylotarg) in combination with conventional antileukemic agents by isobologram analysis in vitro.
Tanaka M; Kano Y; Akutsu M; Tsunoda S; Izumi T; Yazawa Y; Miyawaki S; Mano H; Furukawa Y
Anticancer Res; 2009 Nov; 29(11):4589-96. PubMed ID: 20032408
[TBL] [Abstract][Full Text] [Related]
5. The histone deacetylase inhibitor valproic acid potently augments gemtuzumab ozogamicin-induced apoptosis in acute myeloid leukemic cells.
ten Cate B; Samplonius DF; Bijma T; de Leij LF; Helfrich W; Bremer E
Leukemia; 2007 Feb; 21(2):248-52. PubMed ID: 17122863
[TBL] [Abstract][Full Text] [Related]
6. Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity.
Jedema I; Barge RM; van der Velden VH; Nijmeijer BA; van Dongen JJ; Willemze R; Falkenburg JH
Leukemia; 2004 Feb; 18(2):316-25. PubMed ID: 14614514
[TBL] [Abstract][Full Text] [Related]
7. In vitro experimental (211)At-anti-CD33 antibody therapy of leukaemia cells overcomes cellular resistance seen in vivo against gemtuzumab ozogamicin.
Petrich T; Korkmaz Z; Krull D; Frömke C; Meyer GJ; Knapp WH
Eur J Nucl Med Mol Imaging; 2010 May; 37(5):851-61. PubMed ID: 20107790
[TBL] [Abstract][Full Text] [Related]
8. A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability.
ten Cate B; Bremer E; de Bruyn M; Bijma T; Samplonius D; Schwemmlein M; Huls G; Fey G; Helfrich W
Leukemia; 2009 Aug; 23(8):1389-97. PubMed ID: 19262596
[TBL] [Abstract][Full Text] [Related]
9. Combining inotuzumab ozogamicin with PARP inhibitors olaparib and talazoparib exerts synergistic cytotoxicity in acute lymphoblastic leukemia by inhibiting DNA strand break repair.
Ida N; Okura M; Tanaka S; Hosono N; Yamauchi T
Oncol Rep; 2024 Jul; 52(1):. PubMed ID: 38785163
[TBL] [Abstract][Full Text] [Related]
10. AKT signaling as a novel factor associated with in vitro resistance of human AML to gemtuzumab ozogamicin.
Rosen DB; Harrington KH; Cordeiro JA; Leung LY; Putta S; Lacayo N; Laszlo GS; Gudgeon CJ; Hogge DE; Hawtin RE; Cesano A; Walter RB
PLoS One; 2013; 8(1):e53518. PubMed ID: 23320091
[TBL] [Abstract][Full Text] [Related]
11. FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia.
Norsworthy KJ; Ko CW; Lee JE; Liu J; John CS; Przepiorka D; Farrell AT; Pazdur R
Oncologist; 2018 Sep; 23(9):1103-1108. PubMed ID: 29650683
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxic activity of gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukemia correlates with the expression of protein kinase Syk.
Balaian L; Ball ED
Leukemia; 2006 Dec; 20(12):2093-101. PubMed ID: 17051243
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and resistance of gemtuzumab ozogamicin for acute myeloid leukemia.
Takeshita A
Int J Hematol; 2013 Jun; 97(6):703-16. PubMed ID: 23709007
[TBL] [Abstract][Full Text] [Related]
14. CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance.
Linenberger ML
Leukemia; 2005 Feb; 19(2):176-82. PubMed ID: 15592433
[TBL] [Abstract][Full Text] [Related]
15. Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin.
Cowan AJ; Laszlo GS; Estey EH; Walter RB
Front Biosci (Landmark Ed); 2013 Jun; 18(4):1311-34. PubMed ID: 23747885
[TBL] [Abstract][Full Text] [Related]
16. Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers.
Matsui H; Takeshita A; Naito K; Shinjo K; Shigeno K; Maekawa M; Yamakawa Y; Tanimoto M; Kobayashi M; Ohnishi K; Ohno R
Leukemia; 2002 May; 16(5):813-9. PubMed ID: 11986941
[TBL] [Abstract][Full Text] [Related]
17. CD34(+)/CD38(-) stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab/ozogamicin.
Herrmann H; Cerny-Reiterer S; Gleixner KV; Blatt K; Herndlhofer S; Rabitsch W; Jäger E; Mitterbauer-Hohendanner G; Streubel B; Selzer E; Schwarzinger I; Sperr WR; Valent P
Haematologica; 2012 Feb; 97(2):219-26. PubMed ID: 21993666
[TBL] [Abstract][Full Text] [Related]
18. Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells.
Walter RB; Raden BW; Hong TC; Flowers DA; Bernstein ID; Linenberger ML
Blood; 2003 Aug; 102(4):1466-73. PubMed ID: 12689934
[TBL] [Abstract][Full Text] [Related]
19. Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity.
Walter RB; Raden BW; Kamikura DM; Cooper JA; Bernstein ID
Blood; 2005 Feb; 105(3):1295-302. PubMed ID: 15454492
[TBL] [Abstract][Full Text] [Related]
20. Differential response of human acute myeloid leukemia cells to gemtuzumab ozogamicin in vitro: role of Chk1 and Chk2 phosphorylation and caspase 3.
Amico D; Barbui AM; Erba E; Rambaldi A; Introna M; Golay J
Blood; 2003 Jun; 101(11):4589-97. PubMed ID: 12576328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
